EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications
The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...
AZ
AstraZeneca’s AZD0486 Receives NMPA Greenlight for Clinical Study in B-Cell Leukemia
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, has received approval from the National Medical...
AstraZeneca’s Fasenra Matches Nucala in EGPA Trial and Shows Steroid Reduction Benefits
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has presented results from a Phase III trial...
AstraZeneca Expands Global Footprint with Shanghai Strategic Center
AstraZeneca (AZ, NASDAQ: AZN) has declared that Shanghai is now its fifth global strategic center,...
AstraZeneca Launches Phase I Trial for siRNA Therapy in Collaboration with Silence Therapeutics
AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA...
AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...
AstraZeneca Secures Shareholder Approval for $1 Billion Acquisition of Gracell Biotechnologies
The proposed acquisition of China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) by UK pharmaceuticals giant AstraZeneca...
AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...
AstraZeneca Announces $300 Million Investment in Next-Gen Cell Therapies Manufacturing in the U.S.
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has announced a significant investment of $300...
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...
AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit
AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development
AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for...
AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...
Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...